Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.51 |
| ▸ | NPC1 | O15118 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | LATS1 | O95835 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842772 | 0.80 | PABPC1 (0.49) | RAB9ANPC1SMN1; SMN2KMT2ATP53 | |
| SCHEMBL3742351 | 0.79 | PABPC1 (0.56) | RAB9ANPC1SMN1; SMN2KMT2ATP53 | |
| SCHEMBL22449364 | 0.77 | GAA (0.56) | RAB9ANPC1SMN1; SMN2KMT2ATP53 | |
| SCHEMBL2540067 | 0.77 | BDKRB1 (0.50) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL26384821 | 0.75 | RAB9A (0.41) | RAB9ANPC1SMN1; SMN2KMT2APOLB | |
| SCHEMBL21656898 | 0.73 | GABRA1 (0.39) | SMN1; SMN2KMT2AMEN1GABRA1LATS1 | |
| SCHEMBL4990188 | 0.72 | NPC1 (0.55) | RAB9ANPC1SMN1; SMN2KMT2ATP53 | |
| SCHEMBL464163 | 0.72 | PABPC1 (0.52) | RAB9ANPC1SMN1; SMN2TP53PABPC1 | |
| SCHEMBL5363367 | 0.72 | BDKRB1 (0.46) | SMN1; SMN2KMT2AMEN1GABRA1LATS1 | |
| SCHEMBL2558377 | 0.72 | POLB (0.61) | RAB9ANPC1SMN1; SMN2KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212334-B1 | PROTEASOME INHIBITORS | MILLENNIUM PHARM INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-7838673-B2 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| EP-2212334-A1 | PROTEASOME INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009051581-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099132-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099132-A1 | Proteasome inhibitors | PSMB5, PSMG3, PSMB1 | RAB9A 2935/4885NPC1 1095/4885SMN1; SMN2 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.